Below are the most recent publications written about "Fibrinolysin" by people in Profiles.
-
Mein C, Dugel PU, Feiner L, Drenser K, Miller D, Benz M, Meunier E, Moro L, Fineman MS. PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY. Retina. 2020 Jul; 40(7):1331-1338.
-
McAleer MA, Jakasa I, Raj N, O'Donnell CPF, Lane ME, Rawlings AV, Voegeli R, McLean WHI, Kezic S, Irvine AD. Early-life regional and temporal variation in filaggrin-derived natural moisturizing factor, filaggrin-processing enzyme activity, corneocyte phenotypes and plasmin activity: implications for atopic dermatitis. Br J Dermatol. 2018 08; 179(2):431-441.
-
Birch DG, Benz MS, Miller DM, Antoszyk AN, Markoff J, Kozma P, Meunier E, Sergott RC. EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG Substudy. Retina. 2018 Feb; 38(2):364-378.
-
Greven MA, Garg S, Chiu B, Shah SP, Wolfe J, Fine HF, Roth DB, Robinson J, Mong J, Hsu J, Regillo C, Ho A, Haller JA. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study. Br J Ophthalmol. 2016 Sep; 100(9):1211-5.
-
Khan MA, Shahlaee A, Ho AC. Reopening of a Full-Thickness Macular Hole 2 Years After Pharmacologic Closure With Ocriplasmin. JAMA Ophthalmol. 2015 Nov; 133(11):1362-4.
-
Kaiser PK, Kampik A, Kuppermann BD, Girach A, Rizzo S, Sergott RC. Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion/traction. Retina. 2015 Jun; 35(6):1111-27.
-
Khan MA, Haller JA. Clinical management of vitreomacular traction. Curr Opin Ophthalmol. 2015 May; 26(3):143-8.
-
Sharma P, Juhn A, Houston SK, Fineman M, Chiang A, Ho A, Regillo C. Efficacy of intravitreal ocriplasmin on vitreomacular traction and full-thickness macular holes. Am J Ophthalmol. 2015 May; 159(5):861-7.e2.
-
Dastgheyb S, Parvizi J, Shapiro IM, Hickok NJ, Otto M. Effect of biofilms on recalcitrance of staphylococcal joint infection to antibiotic treatment. J Infect Dis. 2015 Feb 15; 211(4):641-50.
-
Tsui I, Pan CK, Rahimy E, Schwartz SD. Ocriplasmin for vitreoretinal diseases. J Biomed Biotechnol. 2012; 2012:354979.